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Abstract
Masked hypertension, defined as non-elevated clinic blood pressure and elevated out-of-clinic 
blood pressure may be an intermediary stage in the progression from normotension to 
hypertension. We examined the associations of out-of-clinic blood pressure and masked 
hypertension using ambulatory blood pressure monitoring with incident clinic hypertension in the 
Jackson Heart Study, a prospective cohort of African Americans. Analyses included 317 
participants with clinic blood pressure <140/90mmHg, complete ABPM, who were not taking 
antihypertensive medication at baseline in 2000–2004. Masked daytime hypertension was defined 
as mean daytime blood pressure ≥135/85mmHg; masked nighttime hypertension as mean 
nighttime blood pressure ≥120/70mmHg; and masked 24-hour hypertension as mean 24-hour 
blood pressure ≥130/80mmHg. Incident clinic hypertension, assessed at study visits in 2005–2008 
and 2009–2012, was defined as the first visit with clinic systolic/diastolic blood pressure 
≥140/90mmHg or antihypertensive medication use. During a median follow-up of 8.1 years, there 
were 187 (59.0%) incident cases of clinic hypertension. Clinic hypertension developed in 79.2% 
and 42.2% of participants with and without any masked hypertension, 85.7% and 50.4% with and 
without masked daytime hypertension, 79.9% and 43.7% with and without masked nighttime 
hypertension and 85.7% and 48.2% with and without masked 24-hour hypertension, respectively. 
Multivariable-adjusted hazard ratios (95% CI) of incident clinic hypertension for any masked 
hypertension and masked daytime, nighttime, and 24-hour hypertension were 2.13 (1.51–3.02), 
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1.79 (1.24–2.60), 2.22 (1.58–3.12), and 1.91 (1.32–2.75), respectively. These findings suggest that 
ambulatory blood pressure monitoring can identify African Americans at increased risk for 
developing clinic hypertension.
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Introduction
Ambulatory blood pressure (BP) monitoring (ABPM) complements clinic BP by obtaining 
out-of-clinic BP measurements, typically over a 24-hour period.
1
 Many individuals without 
elevated clinic BP have elevated BP on ABPM, a phenomenon termed “masked 
hypertension”.
2
 Individuals with masked hypertension have an increased prevalence of 
subclinical cardiovascular disease (CVD) and risk of CVD events and mortality when 
compared to individuals with sustained normortension, defined as having non-elevated clinic 
and ambulatory BP.
3–8
Masked hypertension may represent an intermediate phenotype between sustained 
normotension, defined as having non-elevated clinic and ambulatory BP, and sustained 
hypertension, defined as having elevated clinic and ambulatory BP.
9–11 However, there are 
few data on the risk for incident hypertension associated with masked hypertension 
particularly among African Americans (AAs), a population with a high prevalence of 
masked hypertension
4
 and also a high risk for incident hypertension.
12
 Previous studies have 
shown that lifestyle modification and pharmacological therapy prevent the onset of 
hypertension.
13–17 If masked hypertension is associated with an increased risk of incident 
hypertension, then these preventive strategies may be appropriate for individuals with 
masked hypertension.
In the current study, we examined the associations of masked daytime, masked nighttime, 
and masked 24-hour hypertension with incident clinic hypertension among participants in 
the Jackson Heart Study (JHS), a cohort study comprised exclusively of African Americans. 
We also examined the association of mean daytime, nighttime, and 24-hour BP with incident 
clinic hypertension. Further, we evaluated whether these associations were independent of 
clinic BP and observed for both participants with prehypertension and normal clinic BP.
Methods
Study Population
The JHS is a population-based prospective cohort study, which was designed to evaluate 
CVD risk among AAs.
18,19 The JHS enrolled 5,301 non-institutionalized AAs, aged ≥21 
years, between 2000 and 2004 from the Atherosclerosis Risk in the Community (ARIC) site 
in Jackson, MS, and a representative sample of urban and rural Jackson, MS metropolitan 
tri-county (Hinds, Madison and Rankin counties) residents, volunteers, randomly selected 
individuals, and secondary family members.
20
 The current analysis was restricted to 1,148 
JHS participants who completed ABPM following the baseline study visit (Visit 1). 
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Participants who did not meet the International Database on ABPM in relation to 
Cardiovascular Outcomes
21
 (IDACO) criteria for valid ABPM (n=102; described below), or 
who were missing clinic BP or information on antihypertensive medication use at the 
baseline visit (n=63) were excluded. Participants whose incident clinic hypertension status 
could not be determined, including those who did not attend Visit 2 (2005–2008) and Visit 3 
(2009–2012) (n=82) or with missing information on BP or antihypertensive medication use 
at both of these visits (n=10) were also excluded as their incident clinic hypertension status 
could not be determined. For the current analysis, we further excluded participants with 
clinic systolic BP (SBP) ≥140 mm Hg or diastolic BP (DBP) ≥90 mmHg or who were on 
antihypertensive medication during the baseline visit (n=574) leaving 317 participants for 
the current analysis. The JHS was approved by the institutional review boards of the 
University of Mississippi Medical Center, Jackson State University, and Tougaloo College. 
The institutional review boards at Columbia University and University of Alabama at 
Birmingham approved the use of JHS data for the current analysis. All participants provided 
written informed consent.
Data Collection & Clinical Covariates
Detailed description of data collection, methodology, specimen collection, and specimen 
processing from the baseline visit (Visit 1) can be found in the online supplement 
(Supplemental Methods) and have been previously described.
19,22 Briefly, data were 
collected at baseline during an in-home interview, clinic examination, and ABPM. During 
the clinic examination, trained technicians measured height, weight and BP, collected blood 
samples, and conducted 2D echocardiography. Antihypertensive medication use was defined 
by self-report. Clinic BP was measured following standardized procedures as described 
below. Left ventricular mass (LVM) and LVM index (LVMI) were derived according to 
American Society of Echocardiography recommendations.
23
 Left ventricular hypertrophy 
(LVH) was defined as LVMI ≥ 89 g/m2 in females and LVMI ≥ 103 g/m2 in males. After the 
clinical examination, participants completed ABPM.
Clinic BP measurement—At each visit, participants rested for at least 5 minutes in an 
upright position with their back and arms supported, feet flat on the floor and legs uncrossed 
prior to having their BP measured. Trained staff conducted two BP measurements in the 
right arm. One minute elapsed between the two measurements. An appropriate cuff size, 
determined from an arm circumference measurement, was used. The JHS Coordinating 
Center conducted quality control by monitoring digit preference for each technician and by 
comparing mean BP measurements within and between trained technicians. The two clinic-
measured BP measurements were averaged for analysis.
Clinic BP was measured using a random zero sphygmomanometer (Hawksley and Sons Ltd., 
Lancing, UK) at Visits 1 and 2 and a semi-automatic oscillometric device (Omron 
HEM-907XL, Omron Healthcare Inc., Lake Forest, Il.) at Visit 3. Among the 4,182 JHS 
participants who attended Visit 2 and had clinic BP measurement, 2,115 were included in a 
BP comparability substudy for which BP was assessed simultaneously, using a Y connector, 
by random zero sphygmomanometer and the Omron HEM-907XL device. As described in 
the Supplemental Methods, the random-zero BP measurements were calibrated to the semi-
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automated device using robust regression. When available, clinic BP from the semi-
automated device was used. In the current analysis, the calibrated BP measurements were 
used at Visit 1 for the 317 participants, and at Visit 2 for 206 participants who did not have 
their BP measured using the semi-automatic oscillometric device.
Incident clinic hypertension was defined as the first follow-up study visit (Visits 2 or 3) with 
clinic SBP ≥ 140 mm Hg, DBP ≥ 90 mm Hg, or antihypertensive medication use.
ABPM—Immediately following the baseline exam, participants were fitted with an ABPM 
device (Spacelabs 90207, Spacelabs, Redmond, WA) on their non-dominant arm. 
Ambulatory BP was recorded every 20 minutes. After 24 hours, the device was removed and 
data were downloaded onto a computer and processed with Medifacts International’s 
Medicom software (Rockville, MD). IDACO criteria were used to define whether the ABPM 
measurement was complete. Specifically, participants were considered to have a complete 
ABPM if they had ≥10 daytime (10:00 to 20:00) and ≥5 nighttime (00:00 to 06:00) SBP and 
DBP measurements.
21
 Mean daytime SBP and DBP, mean nighttime SBP and DBP, and 
mean 24-hour SBP and DBP were calculated by averaging the readings during the daytime, 
nighttime and the entire ABPM period, respectively.
Daytime hypertension was defined as mean daytime SBP ≥ 135mmHg or mean daytime 
DBP ≥ 85mmHg, nighttime hypertension was defined as mean nighttime SBP ≥ 120mmHg 
or mean nighttime DBP ≥ 70mmHg and 24-hour hypertension was defined as mean SBP ≥ 
130mmHg or mean DBP ≥ 80mmHg based on all available readings. Since the current 
analysis was restricted to participants with non-elevated clinic-measured BP (clinic 
SBP/DBP < 140mmHg/90 mm Hg), participants with daytime, nighttime and 24-hour 
hypertension had masked daytime, masked nighttime and masked 24-hour hypertension, 
respectively. Additionally, participants with masked daytime, nighttime or 24-hour 
hypertension were categorized as having any masked hypertension.
Statistical analyses—Baseline participant characteristics were calculated for the 
analytical sample as mean ± standard deviation (SD) or percentages. The prevalence of any 
masked hypertension and masked daytime, nighttime and 24-hour hypertension was 
calculated. The percentage of participants developing hypertension was calculated by 
quartile of mean daytime, nighttime, and 24-hour SBP. Since we do not know the exact date 
participants developed hypertension, only that it developed between two study visits, 
interval-censored Cox regression
24
 was used to calculate hazard ratios (HRs) for incident 
hypertension associated with higher quartiles (quartiles 2, 3 and 4) versus lowest quartile 
(quartile 1) of mean daytime, nighttime, and, separately, 24-hour SBP. Three models with 
progressive adjustment were estimated. Models adjusted for age and sex (Model 1), 
variables in the Framingham hypertension risk prediction score
25
 including age, sex, BMI, 
clinic SBP, parental history of hypertension, smoking status, age by clinic DBP interaction 
(Model 2). A final model included additional adjustment for diabetes, education level less 
than high school, alcohol consumption, total physical activity score, and reduced estimated 
glomerular filtration rate (eGFR) (Model 3). The above analyses were repeated for higher 
quartiles (quartiles 2, 3 and 4) versus the lowest quartile (quartile 1) of mean daytime, 
nighttime and 24-hour DBP. HRs for incident hypertension associated with SD higher mean 
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daytime, nighttime and 24-hour SBP and DBP were also calculated. The percentage of 
participants developing hypertension was calculated for those with and without any masked 
hypertension, and masked daytime, nighttime, and 24-hour hypertension. HRs for incident 
hypertension associated with any masked hypertension, and masked daytime, nighttime, and 
24-hour hypertension were calculated with adjustment for covariates in three models as 
described above.
As prior studies have demonstrated that prehypertension is associated with a higher risk for 
incident hypertension compared to normal clinic BP,
26–29 and that an overlap exists between 
masked hypertension and prehypertension,
4,30 secondary analyses were performed after 
stratifying the sample into participants with prehypertension or normal CBP at baseline. 
Prehypertension was defined as mean clinic SBP 120–139mmHg or mean clinic DBP 80–
89mmHg. Normal clinic BP was defined as mean clinic SBP < 120mmHg and mean clinic 
DBP < 80mmHg. Analyses were performed using SAS Version 9.4 (SAS Institute, Cary 
NC) and Stata Version13.1 (Stata Inc., College Station, TX).
Results
Baseline Characteristics
The mean ± SD age of participants included in the current analysis was 54.8 ± 11.1 years 
and 69.1% were female (Table S1). The prevalence of prehypertension was 57.1%. The 
prevalence of masked daytime hypertension, masked nighttime hypertension, and masked 
24-hour hypertension, were 22.3%, 42.3%, and 28.7%, respectively. Overall, 45.4% of 
participants had any masked hypertension. Compared with JHS participants who were not 
included in the analyses, those who were included were older, more likely to be female, had 
higher high-density lipoprotein cholesterol, had a higher LVMI, were more likely to have 
LVH, were less likely to be a current smoker, and had higher clinic SBP and lower clinic 
DBP.
Ambulatory BP and Incident Clinic Hypertension
The median time between Visit 1 and Visit 2 and Visit 1 and Visit 3 was 5.0 and 8.1 years, 
respectively. During follow-up, there were 187 cases (59.0%) of incident clinic 
hypertension; 124 cases at Visit 2 and an additional 63 cases at Visit 3. Of the 187 cases of 
incident hypertension, 44 (23.5%) had incident hypertension based on having clinic SBP ≥ 
140 mmHg or clinic DBP ≥ 90 mmHg without taking antihypertensive medication and 120 
(64.2%) had incident hypertension based on taking antihypertensive medication without 
having either clinic SBP ≥ 140 mmHg or clinic DBP ≥ 90 mmHg at a follow-up visit. 
Finally, 23 (12.3%) had incident hypertension based on having clinic SBP ≥ 140 mmHg or 
clinic DBP ≥ 90 mmHg at a follow-up visit and were also taking antihypertensive 
medication.
After adjustment for age and sex, higher quartiles of daytime, nighttime and 24-hour SBP 
were associated with an increased risk of incident hypertension (Model 1, Table 1). These 
associations remained present after further multivariable adjustment. Higher quartiles of 
daytime, nighttime and 24-hour DBP were also associated with an increased risk of incident 
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clinic hypertension before and after multivariable adjustment (Table S2). When modeled as 
continuous variables, higher daytime, nighttime, and 24-hour SBP and DBP were associated 
with an increased risk of incident clinic hypertension (Table S3).
Masked Hypertension and Incident Clinic Hypertension
Overall, 79.2% and 42.2% of participants with and without any masked hypertension 
developed incident clinic hypertension during follow-up (Figure 1). The proportion of 
participants developing incident clinic hypertension was higher among participants with 
versus without masked daytime hypertension (85.7% versus 50.4%), masked nighttime 
hypertension (79.9% versus 43.7%) and masked 24-hour hypertension (85.7% versus 
48.2%). After multivariable adjustment, any masked hypertension and masked daytime, 
nighttime, and 24-hour hypertension were each associated with an increased risk of incident 
clinic hypertension (Table 2).
Masked Hypertension and the Risk of Incident Clinic Hypertension Stratified by 
Prehypertension Status
Higher daytime, nighttime, and 24-hour SBP and DBP were each associated with an 
increased risk of clinic hypertension among participants with prehypertension. (Table S4). 
Among individuals with normal clinic BP, higher daytime, nighttime, and 24-hour SBP were 
associated with an increased risk of incident clinic hypertension. Higher nighttime and 24-
hour DBP, but not daytime DBP, were associated with incident clinic hypertension in 
participants with normal CBP. Also, among participants with prehypertension, any masked 
hypertension, as well as each type of masked hypertension, was associated with an increased 
risk of clinic hypertension after multivariable adjustment (Table S5). Among participants 
with normal clinic BP, any masked hypertension and masked nighttime hypertension were 
associated with an increased risk of incident clinic hypertension. Any masked hypertension 
and incident hypertension occurred among 51.9% (94/181) of participants with 
prehypertension and 14.7% (20/136 of participants with normal clinic BP. Among 
participants with prehypertension, 33.7% (61/181) had masked daytime hypertension and 
incident hypertension; 48.1% (87/181) had masked nighttime hypertension and incident 
hypertension; and 39.2% (71/181) had masked 24-hour hypertension and incident 
hypertension. Among participants with normal clinic BP, these estimates were 3.7% (5/136), 
14.7% (20/136) and 5.1% (7/136), respectively.
Discussion
In the current population-based sample of AAs with non-elevated clinic BP at baseline, 
higher levels of ambulatory BP were associated with an increased risk for incident clinic 
hypertension. Additionally, having any masked hypertension was associated with an 
increased risk for incident clinic hypertension as was each type of masked hypertension. 
Only a few studies, mostly in Whites, have examined the association between masked 
hypertension and the development of hypertension.
7,31–33 In an outpatient sample of 34 
Spanish children and adolescents, aged 6 to 18 years old, with masked daytime 
hypertension, Lurbe et al.
31
 showed that after a median follow-up of 37 months there were 3 
participants (8.8%) who developed sustained hypertension. No participants in the control 
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group of 200 children and adolescents with sustained normotension progressed to sustained 
hypertension. In the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study, 
which enrolled a population-sample from Monza, Italy
32
, 47.1% of participants with masked 
24-hour hypertension developed sustained hypertension after 10 years of follow-up 
compared with 18.2% of those with sustained normotension. Also, in a study of 232 
Canadian public insurance employees with masked daytime hypertension, sustained 
hypertension was present in 61 (26.3%) participants after 3 years and 81 (34.9%) 
participants after 5 years of follow-up.
33
 In that study, the progression from sustained 
normotension to sustained hypertension was not reported.
An important limitation of our study is that ABPM was not performed at the follow-up 
visits. Therefore, the current study was unable to confirm whether participants categorized 
as having clinic hypertension at follow-up had sustained hypertension or white coat 
hypertension, defined as elevated clinic BP but non-elevated ambulatory BP. However, prior 
studies have shown that the progression of masked hypertension to white coat hypertension 
is uncommon. In the PAMELA study,
32
 and in a study by Trudel et al.
33
, only 7.6% and 
0.5%, respectively, of participants with masked hypertension at baseline had white coat 
hypertension during follow-up. Therefore, it is likely that most of the participants in the 
current study with incident clinic hypertension during follow-up had sustained hypertension. 
The current study was also unable to determine the percentage of participants with masked 
hypertension at baseline who continued to have masked hypertension or alternatively had 
sustained normotension at follow-up. In the PAMELA study, among participants with 
masked hypertension at baseline and who did not have elevated clinic BP at follow-up, 
51.9% and 48.1% had masked hypertension and sustained normotension, respectively, 
during follow-up.
32
In younger adults, clinic BP is, on average, lower than ambulatory BP.
9,10,34,35 It has been 
proposed that during the aging process, some individuals reach a stage where their 
ambulatory BP exceeds the threshold for a diagnosis of hypertension while their clinic BP is 
not yet in the hypertensive range;
9,10 many of these individuals are likely to have 
prehypertension. We have previously reported that there is a substantial overlap between 
masked hypertension and prehypertension.
30
 Given that prehypertension is associated with 
an increased risk of incident clinic hypertension compared to normal clinic blood pressure,
29 
prehypertension may explain the increased risk for clinic hypertension among individuals 
with masked hypertension. However, in the current study, the association between any 
masked hypertension and incident clinic hypertension was independent of clinic BP level, 
and this association was also similar for participants with prehypertension and those with 
normal clinic BP.
In our study, masked nighttime hypertension, but not masked daytime or masked 24-hour 
hypertension, was associated with incident clinic hypertension among those with normal 
clinic BP. Prior studies have shown that compared to Whites, AAs have a higher prevalence 
of nighttime hypertension.
36–38 The underlying mechanisms linking nighttime hypertension 
to incident clinic hypertension in AAs are unknown. Psychosocial stress, sleep apnea as well 
as biological factors such as arterial stiffness, inflammation, endothelial dysfunction, and 
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salt sensitivity may be possible mechanisms.
39–42 Future studies should examine the factors 
linking masked nighttime hypertension to incident clinic hypertension among AAs.
Given the substantial morbidity and mortality associated with hypertension, earlier 
identification of individuals at a high risk for developing hypertension is of paramount 
importance. The results of our study suggest that the identification of masked hypertension 
among individuals with non-elevated clinic BP using ABPM may identify those at highest 
risk for incident clinic hypertension. Previous studies
15,16,26,43,44 have demonstrated that 
lifestyle modification and pharmacological therapy may delay the onset of hypertension 
among high-risk individuals including those with prehypertension. These preventive 
strategies may prove to be most effective for not only the subset of individuals with 
prehypertension who have masked hypertension but also for those individuals with normal 
CBP and masked hypertension. Furthermore, in the current study, 11.1% of participants had 
LVH at baseline. Diaz et al.
4
 previously demonstrated that among JHS participants, masked 
hypertension was associated with increased LVMI. Given the increased CVD risk associated 
with LVH
45
, individuals with masked hypertension and LVH may represent a high-risk 
group that might benefit from antihypertensive medication initiation prior to the 
development of clinic hypertension. Randomized trials are needed to determine whether 
lifestyle modification and pharmacological therapy delay hypertension onset and reverse 
cardiovascular end-organ damage among individuals with masked hypertension.
There are several strengths of the current study. We used data from a population-based 
sample comprised entirely of AAs. There have been few prior investigations of ABPM 
among AAs,
4,46 and this population has a high risk for masked hypertension
4
 and incident 
clinic hypertension.
12
 Also, given the broad data collection in the JHS, we were able to 
control for multiple potential confounders. We were also able to examine several types of 
masked hypertension including masked daytime, nighttime, and 24-hour hypertension, as 
well as determine the risk of incident clinic hypertension stratified by prehypertension 
status. In addition to ABPM not being conducted at a follow-up visit in the JHS, there were 
also other possible limitations. Only a sub-sample of JHS participants had ABPM performed 
at the baseline visit. Information regarding napping during the daytime period and 
awakening during the nighttime period, which may impact estimates of daytime and 
nighttime BP, was not collected. In addition, the JHS did not conduct home BP monitoring 
(HBPM), another out-of-clinic approach for measuring BP, which also can be used to 
determine masked hypertension. Some evidence suggests that many individuals have masked 
hypertension on either ABPM or HBPM, but not on both.
47
 Therefore, masked hypertension 
on ABPM vs. HBPM may represent different out-of-clinic BP phenotypes. We were unable 
to assess the association of masked hypertension on HBPM and incident hypertension within 
the JHS.
Perspectives
Among AAs with non-elevated clinic BP and who were not taking antihypertensive 
medication, masked hypertension was associated with an increased risk for the development 
of clinic hypertension. The association between any masked hypertension and incident clinic 
hypertension was present after adjustment for clinic BP, and was similar among participants 
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with prehypertension and normal clinic BP. Also, daytime, nighttime and 24-hour masked 
hypertension was each associated with incident clinic hypertension. The results of the 
current study suggest that among AA adults with non-elevated clinic BP, ABPM can identify 
those who are at increased risk for developing clinic hypertension.
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Refer to Web version on PubMed Central for supplementary material.
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• We examined the associations of masked hypertension and its subtypes (masked 
daytime, nighttime, and 24-hour hypertension) with incident clinic hypertension 
among a population-based cohort of AAs.
• We also evaluated whether these associations were independent of clinic BP 
level and consistent for those with prehypertension and, separately, normal clinic 
BP.
What is Relevant?
• It has been hypothesized that masked hypertension represents an intermediate 
phenotype between normotension and hypertension.
• Few population-based studies have examined the association between masked 
hypertension and incident hypertension, and none have examined this 
association in AAs, who have a high prevalence of masked hypertension.
Summary
• Among a large population-based cohort study of AAs with non-elevated clinic 
blood pressure, participants with any masked hypertension had twice the risk of 
incident clinic hypertension compared to participants without masked 
hypertension over an 8 year follow up period.
• Among participants with either prehypertension or normal clinic BP, masked 
hypertension was associated with increased risk of incident clinic hypertension.
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Percent developing clinic hypertension in individuals with and without any masked 
hypertension, masked daytime hypertension, masked nighttime hypertension, and masked 
24-hour hypertension.
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